ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Antiphospholipid Syndrome Poster (0069–0083)

8:30AM-10:30AM: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)

8:30AM-10:30AM: Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)

8:30AM-10:30AM: Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

8:30AM-10:30AM: Osteoarthritis – Clinical Poster I (0210–0224)

8:30AM-10:30AM: Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

8:30AM-10:30AM: Psychology/Social Sciences Poster (0266–0267)

8:30AM-10:30AM: RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

8:30AM-10:30AM: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

8:30AM-10:30AM: Vasculitis – ANCA-Associated Poster (0414–0436)

9:00AM-10:00AM: Abstracts: Immunological Complications of Therapy (0437–0440)

9:00AM-10:00AM: Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)

9:30AM-10:30AM: Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)

9:30AM-10:30AM: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)

10:30AM-11:30AM: Abstracts: Health Services Research (0462–0465)

10:30AM-11:30AM: Abstracts: Imaging of Rheumatic Diseases (0466–0469)

10:30AM-11:30AM: Abstracts: RA – Etiology & Pathogenesis (0458–0461)

10:30AM-12:00PM: Plenary I (0453–0457)

11:00AM-12:00PM: Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)

11:00AM-12:00PM: Abstracts: SLE – Animal Models (0470–0473)

2:00PM-3:30PM: Abstracts: Osteoarthritis – Clinical (0478–0483)

2:00PM-3:00PM: Abstracts: Professional Education (0484–0487)

2:00PM-3:00PM: Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

3:30PM-4:30PM: Abstracts: Healthcare Disparities in Rheumatology (0492–0495)

3:30PM-5:00PM: Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)

3:30PM-5:00PM: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)

Sunday, November 7, 2021

8:30AM-10:30AM: Cytokines & Cell Trafficking Poster (0508–0516)

8:30AM-10:30AM: Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Osteoarthritis – Clinical Poster II (0723–0738)

8:30AM-10:30AM: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Patient Perspectives Poster (PP01–PP09)

8:30AM-10:30AM: Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Research Methodology Poster (0846–0854)

8:30AM-10:30AM: SLE – Animal Models Poster (0534–0540)

8:30AM-10:30AM: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

9:00AM-10:00AM: Abstracts: Antiphospholipid Syndrome (0948–0951)

9:00AM-10:00AM: Abstracts: Osteoarthritis & Joint Biology – Basic Science (0940–0943)

9:00AM-10:00AM: Abstracts: Spondyloarthritis Including PsA – Basic Science (0944–0947)

9:00AM-10:00AM: Abstracts: Vasculitis – ANCA-Associated (0952–0955)

10:30AM-11:30AM: Abstracts: Infection-related Rheumatic Disease (0962–0965)

10:30AM-11:30AM: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0966–0969)

10:30AM-12:00PM: Plenary II (0956–0961)

2:00PM-3:30PM: Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

2:00PM-3:00PM: Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Bugs & Drugs (0980–0983)

2:00PM-3:00PM: Abstracts: SLE – Etiology & Pathogenesis (0970–0973)

3:30PM-4:30PM: Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)

3:30PM-4:30PM: Patient Perspectives (PP10–PP13)

4:00PM-5:00PM: Abstracts: Epidemiology & Public Health I: Risk in Rheumatic Diseases (0988–0991)

Monday, November 8, 2021

8:30AM-10:30AM: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Health Services Research Poster II: Care Models and Innovation (1061–1082)

8:30AM-10:30AM: Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Osteoarthritis – Clinical Poster III (1118–1134)

8:30AM-10:30AM: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

8:30AM-10:30AM: Patient Education/Community Programs Poster (1150–1152)

8:30AM-10:30AM: Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

8:30AM-10:30AM: Pediatric Rheumatology – Basic Science Poster (1007–1013)

8:30AM-10:30AM: Professional Education Poster (1170–1195)

8:30AM-10:30AM: RA – Animal Models Poster (1014–1021)

8:30AM-10:30AM: RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

9:00AM-10:00AM: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)

10:30AM-11:30AM: Abstracts: Innate Immunity (1430–1433)

10:30AM-11:30AM: Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (1434–1437)

10:30AM-12:00PM: Plenary III (1424–1429)

2:00PM-3:30PM: Abstracts: Clinical Epidemiology (1446–1451)

2:00PM-3:00PM: Abstracts: Cytokines & Cell Trafficking (1438–1441)

2:00PM-3:00PM: Abstracts: RA – Treatments II: New Findings in Established Therapies (1442–1445)

3:30PM-5:00PM: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

3:30PM-5:00PM: Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

4:00PM-5:00PM: Abstracts: Reproductive Issues in Rheumatic Disorders (1464–1467)

Tuesday, November 9, 2021

8:30AM-10:30AM: Immunological Complications of Therapy Poster (1516–1529)

8:30AM-10:30AM: Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Late-Breaking Posters (L01 - L15)

8:30AM-10:30AM: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Orthopedics, Low Back Pain, & Rehabilitation Poster (1584–1588)

8:30AM-10:30AM: Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

8:30AM-10:30AM: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

8:30AM-10:30AM: Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)

8:30AM-10:30AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

9:00AM-10:00AM: Abstracts: RA – Animal Models (1889–1892)

10:30AM-11:30AM: Abstracts: Measures & Measurement of Healthcare Quality (1893–1896)

10:30AM-11:30AM: Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (1897–1900)

10:30AM-11:30AM: Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (1901–1904)

10:30AM-12:00PM: Late-Breaking Abstracts (L16 - L21)

2:00PM-3:00PM: Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1905–1908)

2:00PM-3:30PM: Abstracts: Patient Outcomes, Preferences, & Attitudes (1909–1914)

2:00PM-3:30PM: Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Heart & Lung (1915–1918)

2:00PM-3:30PM: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes II (1919–1922)

3:30PM-4:30PM: Abstracts: Epidemiology & Public Health II: Inflammatory Arthritis (1923–1926)

3:30PM-4:30PM: Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)

3:30PM-4:30PM: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Predictors & Longitudinal Outcomes (1931–1934)

4:00PM-5:00PM: Abstracts: Genetics, Genomics & Proteomics (1935–1938)

4:00PM-5:00PM: Abstracts: RA – Treatments I: Safety & Harms (1939–1942)

4:00PM-5:00PM: Abstracts: Spondyloarthritis Including PsA – Treatment II: Biologic Therapies (1943–1946)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].